| Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes B Zinman, C Wanner, JM Lachin, D Fitchett, E Bluhmki, S Hantel, ... New england journal of medicine 373 (22), 2117-2128, 2015 | 12177 | 2015 |
| Empagliflozin and progression of kidney disease in type 2 diabetes C Wanner, SE Inzucchi, JM Lachin, D Fitchett, M von Eynatten, ... New England Journal of Medicine 375 (4), 323-334, 2016 | 3838 | 2016 |
| Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus DZI Cherney, BA Perkins, N Soleymanlou, M Maione, V Lai, A Lee, ... Circulation 129 (5), 587-597, 2014 | 1357 | 2014 |
| Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial J Rosenstock, V Perkovic, OE Johansen, ME Cooper, SE Kahn, N Marx, ... Jama 321 (1), 69-79, 2019 | 1076 | 2019 |
| Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial D Fitchett, B Zinman, C Wanner, JM Lachin, S Hantel, A Salsali, ... European heart journal 37 (19), 1526-1534, 2016 | 1074 | 2016 |
| How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial SE Inzucchi, B Zinman, D Fitchett, C Wanner, E Ferrannini, ... Diabetes care 41 (2), 356-363, 2018 | 670 | 2018 |
| Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial J Rosenstock, SE Kahn, OE Johansen, B Zinman, MA Espeland, ... Jama 322 (12), 1155-1166, 2019 | 582 | 2019 |
| The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus DZI Cherney, BA Perkins, N Soleymanlou, R Har, N Fagan, OE Johansen, ... Cardiovascular diabetology 13, 1-8, 2014 | 523 | 2014 |
| Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes R Chilton, I Tikkanen, CP Cannon, S Crowe, HJ Woerle, UC Broedl, ... Diabetes, Obesity and Metabolism 17 (12), 1180-1193, 2015 | 514 | 2015 |
| SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials SE Inzucchi, B Zinman, C Wanner, R Ferrari, D Fitchett, S Hantel, ... Diabetes and vascular disease Research 12 (2), 90-100, 2015 | 510 | 2015 |
| Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme OE Johansen, D Neubacher, M von Eynatten, S Patel, HJ Woerle Cardiovascular diabetology 11, 1-10, 2012 | 357 | 2012 |
| Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial D Fitchett, SE Inzucchi, CP Cannon, DK McGuire, BM Scirica, ... Circulation 139 (11), 1384-1395, 2019 | 298 | 2019 |
| Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™) B Zinman, SE Inzucchi, JM Lachin, C Wanner, R Ferrari, D Fitchett, ... Cardiovascular diabetology 13, 1-8, 2014 | 282 | 2014 |
| Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial BA Perkins, DZI Cherney, H Partridge, N Soleymanlou, H Tschirhart, ... Diabetes care 37 (5), 1480-1483, 2014 | 280 | 2014 |
| Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial D Fitchett, J Butler, P van de Borne, B Zinman, JM Lachin, C Wanner, ... European heart journal 39 (5), 363-370, 2018 | 267 | 2018 |
| Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®) N Marx, J Rosenstock, SE Kahn, B Zinman, JJ Kastelein, JM Lachin, ... Diabetes and Vascular Disease Research 12 (3), 164-174, 2015 | 245 | 2015 |
| Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin DZI Cherney, ME Cooper, I Tikkanen, E Pfarr, OE Johansen, HJ Woerle, ... Kidney international 93 (1), 231-244, 2018 | 222 | 2018 |
| Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4‐week, randomized, placebo‐controlled trial (EASE‐1) TR Pieber, S Famulla, J Eilbracht, J Cescutti, N Soleymanlou, ... Diabetes, Obesity and Metabolism 17 (10), 928-935, 2015 | 201 | 2015 |
| Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies JW Haukeland, TB Dahl, A Yndestad, IP Gladhaug, EM Løberg, ... European journal of endocrinology 166 (3), 503-510, 2012 | 200 | 2012 |
| Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial C Wanner, HJL Heerspink, B Zinman, SE Inzucchi, A Koitka-Weber, ... Journal of the American Society of Nephrology 29 (11), 2755-2769, 2018 | 189 | 2018 |
